Medgenics (MDGN)

[BollixMeArse]

Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients

Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients on dialysis with end-stage renal disease (“ESRD”).

observations from the Company’s prior Phase I/II study in anemic pre-dialysis patients.

Hemoglobin in these patients remained in the desired 9-11 g/dl range for approximately 2-4 months, without needing any EPO or other ESA injections. Notably, at no point following EPODURE treatment did the concentration of EPO in the serum of the patients exceed the typical normal range and always remained under 100 mU/ml.